Denali Therapeutics Announces Closing of a $316 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 24 2022 - 3:30PM
Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the closing
of its upsized underwritten public offering of 11,933,962 shares of
its common stock at a price to the public of $26.50 per share,
which includes the exercise in full by the underwriters of their
option to purchase additional shares. The total gross proceeds from
the offering, before deducting underwriters’ discounts and
commissions and estimated offering expenses, are approximately $316
million.
Goldman Sachs & Co. LLC, J.P. Morgan
Securities LLC and Jefferies LLC acted as joint book-running
managers. Berenberg Capital Markets LLC, Cantor Fitzgerald &
Co. and H.C. Wainwright & Co., LLC acted as co-managers for the
offering.
The offering was made pursuant to a Registration
Statement on Form S-3, which was automatically effective upon
filing with the SEC on February 28, 2022, and the final prospectus
supplement relating to the offering, dated October 19, 2022, which
was filed on October 20, 2022. These documents can be accessed for
free through the SEC’s website at www.sec.gov or by request
from:
Goldman Sachs & Co. LLC, Attention:
Prospectus Department, 200 West Street, New York, NY 10282,
telephone: 1-866-471-2526, fax: 212-902-9316, email:
prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, telephone: 1-866-803-9204 or by email:
prospectus-eq_fi@jpmchase.com; or Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, New York, NY
10022, by telephone at (877) 821-7388, or by email at
prospectus_department@jefferies.com.
This press release does not constitute an offer
to sell or a solicitation of an offer to buy, nor will there be any
sale of these securities in any state or other jurisdiction in
which such offer, solicitation, or sale would be unlawful before
registration or qualification under the securities laws of that
state or jurisdiction.
About Denali Therapeutics
Denali Therapeutics is a biopharmaceutical
company developing a broad portfolio of product candidates
engineered to cross the blood-brain barrier (BBB) for
neurodegenerative diseases. Denali Therapeutics pursues new
treatments by rigorously assessing genetically validated targets,
engineering delivery across the BBB and guiding development through
biomarkers that demonstrate target and pathway engagement. Denali
Therapeutics is based in South San Francisco.
Investor Relations Contact:
Laura Hansen, Ph.D.Vice President, Investor Relations(650)
452-2747hansen@dnli.com
Media Contact:
dna CommunicationsAngela Salerno-RobinSenior Vice President,
Media Relations, Healthcare+ 1 212 445
8219Asalerno-robin@dna-comms.com
Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
From Jul 2023 to Jul 2024